Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Pancreatic Adenocarcinoma 1 Multiple Myeloma 1 Metastatic Pancreatic Adenocarcinoma 1 Esophageal Neoplasms 1

Interventions

Dexamethasone 307 Bortezomib 161 Lenalidomide 130 pomalidomide 112 daratumumab 94 carfilzomib 69 Calcium Dobesilate 41 Cyclophosphamide 40 belantamab mafodotin 31 elotuzumab 30 fludarabine 27 ixazomib 23 isatuximab 21 Melphalan 21 venetoclax 18 selinexor 17 talquetamab 15 Prednisone 15 plerixafor 14 Panobinostat 14 Granulocyte Colony-Stimulating Factor 14 Injections 12 idecabtagene vicleucel 11 Zoledronic Acid 11 Thalidomide 11 Azacitidine 11 pembrolizumab 10 tocilizumab 9 nirogacestat 9 liposomal doxorubicin 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Multiple Myeloma × 4-fluorobenzoyl-TN-14003 × Clear all

NCT03246529 2026-01-15

GENESIS

BioLineRx, Ltd.

Phase 3 Active not recruiting

180 enrolled 22 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡